Unoprostone

Unoprostone

SCHEMBL2469324

CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C/CCCC(=O)O)[C@@H](O)C[C@H]1O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 2/20 0.73
▸ ADORA3 P0DMS8 2/20 0.73
▸ SLC6A2 P23975 2/20 0.73
▸ ADRA2C P18825 1/20 0.73
▸ HTR2B P41595 1/20 0.73
▸ MC3R P41968 1/20 0.73
▸ SLC6A3 Q01959 1/20 0.73
▸ PDE4D Q08499 1/20 0.73
▸ SCN5A Q14524 1/20 0.73
▸ TBXA2R P21731 4/20 0.57
▸ PTGFR P43088 3/20 0.57
▸ LMNA P02545 3/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ PTGER1 P34995 2/20 0.57
▸ PTGER3 P43115 2/20 0.57
▸ SLCO2A1 Q92959 2/20 0.57
▸ PTGER4 P35408 1/20 0.57
▸ PTGDR Q13258 1/20 0.57
▸ KMT2A Q03164 2/20 0.52
▸ MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Unoprostone SCHEMBL194651 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
SCHEMBL6409062 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL18605546 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL1286324 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL2469329 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL14957866 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
SCHEMBL6409055 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL1286326 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL22965277 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL572177 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS TECHFIELDS PHARMA CO., LTD (CN) 2023-07-27 — — US disclosed
US-11541029-B2 High penetration compositions and their applications TECHFIELDS PHARMA CO., LTD. (CN) 2023-01-03 — — US disclosed
US-20130131106-A1 BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE INSPIRE PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed
US-20110269689-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS PREMIER RESEARCH INTERNATIONAL, LLC 2011-11-03 — — US disclosed
EP-2370406-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS Yu, Chongxi (US) 2011-10-05 — — EP disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 — — US disclosed
WO-2010065936-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS YU CHONGXI (US) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269689-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS SLC19A1, HIRA, SLC43A1 PGR 996/4885ADORA3 1145/4885SLC6A2 54/4885
US-11541029-B2 High penetration compositions and their applications SLC19A1, HIRA, SLC43A1 PGR 996/4885ADORA3 1145/4885SLC6A2 54/4885
US-20130131106-A1 BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE ROCK2, ROCK1, RHOA PGR 4537/4885ADORA3 3954/4885SLC6A2 4368/4885
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS SLC5A7, SLC19A1, SLC43A1 PGR 1262/4885ADORA3 721/4885SLC6A2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback